origins & foundations
Why do we are here?
In 2004, for the first time in history an NK-1R antagonist was used successfully for cancer treatment. Dr. Miguel Munoz was the pioneer in this novel therapeutic approach. Since then he has been constantly publishing the findings of his cancer research for the scientific community, with over 100 publications. His research regarding NK-1R antagonists and cancer is increasingly recognised worldwide.
Meanwhile, Prof. Alan Nimmo accumulated almost 40 years of experience in NK-1R and neuroinflammation. Being aware of the potential clinical value of such a drug for patients, he used his connections with Big Pharma in order to acquire the best NK-1R antagonist available for clinical development, CHB-001.
Dr. Munoz and Prof. Nimmo hold over 5,000 scientific citations. Now joining efforts and with the support of a strong professional team, they are thrilled to translate years of top research to deliver patient outcomes.